Guardant Health
Guardant Health raises $360M Series F at $12B valuation
Guardant Health: Series F Funding Round
Guardant Health has successfully raised $360M in Series F funding, reaching a valuation of $12B.
Company Overview
Liquid biopsy cancer detection
Funding Details
The Series F round was led by SoftBank Vision Fund, with participation from Baillie Gifford, T. Rowe Price, Khosla Ventures, Sequoia Capital.
Company Information
- Headquarters: 505 Penobscot Drive, Redwood City, CA 94063
- Founded: 2012
- Employees: 1400+
- Category: Biotech
Investment
Guardant Health plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series F
- Baillie Gifford: Verified investor in Series F
- T. Rowe Price: Verified investor in Series F
- Khosla Ventures: Verified investor in Series F
- Sequoia Capital: Verified investor in Series F
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free